Skip to main content
Top
Published in: Diabetology International 2/2013

01-06-2013 | Original Article

Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients

Authors: Takuya Harayama, Toshihide Yoshida, Keiji Yoshioka, Akinori Kogure, Ryosuke Sakai, Tetsuya Yasui, Yuriko Kondo, Michiaki Fukui, Goji Hasegawa, Naoto Nakamura

Published in: Diabetology International | Issue 2/2013

Login to get access

Abstract

Objective

To clarify the correlation between weight loss and the improvement of diabetes mellitus among obese patients with type 2 diabetes.

Patients and methods

One hundred and eighty untreated obese patients with type 2 diabetes with HOMA-R over 1.6 and HbA1c over 6.9 were enrolled to achieve weight reduction over 6 months with diet and exercise intervention. Six months after treatment, the subjects underwent a 75 g glucose tolerance test (OGTT), were diagnosed as the normal type, IGT type, or diabetic type, and potential factors for the normalization of glycemia were analyzed.

Results

Six-month treatment led to a significant reduction (P < 0.001) of body weight and amelioration of glycemic factors. Thirty-two subjects were diagnosed by the 75 g OGTT as normal type, 60 as the IGT type, and 88 as diabetic type. Weight reduction was significantly (P < 0.001) greater in the normal type (15.7–31.5 %) than in the diabetic type (1.8–20.2 %). The normal type had a shorter duration of obesity and diabetes than the diabetic type. Furthermore, HbA1c was reduced to below 6.9 for 168 patients but not for 12 patients. For the former, body weight reduction was 3.1–31.5 %; for the latter it was less than 3 %.

Conclusion

Six-month obesity treatment of obese type 2 diabetic patients led to significant weight loss and the amelioration of glycemic factors. For obese type 2 diabetes, more than 3 % weight reduction is needed to improve glycemic control, and more than 15 % weight reduction and, in addition, short duration of obesity and diabetes (3.5 ± 2.5 years), are required to normalize glucose tolerance.
Literature
1.
go back to reference Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000;2:105–12.PubMedCrossRef Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000;2:105–12.PubMedCrossRef
2.
go back to reference Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS. Dexfenfluramine in NIDDM patients. Diabetes Care. 1997;20:1122–7.PubMedCrossRef Chow CC, Ko GT, Tsang LW, Yeung VT, Chan JC, Cockram CS. Dexfenfluramine in NIDDM patients. Diabetes Care. 1997;20:1122–7.PubMedCrossRef
3.
go back to reference Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus: The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Diabetol Int. 2010;1:2–20.CrossRef Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Ueki K. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus: The Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus. Diabetol Int. 2010;1:2–20.CrossRef
4.
go back to reference Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society (JDS): International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, Tominaga M, Oikawa S, Noda M, Kawamura T, Sanke T, Namba M, Hashiramoto M, Sasahara T, Nishio Y, Kuwa K, Ueki K, Takei I, Umemoto M, Murakami M, Yamakado M, Yatomi Y, Ohashi H. Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society (JDS): International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Diabetol Int. 2012;3:8–10.
5.
go back to reference Harayama T, Kusunoki C, Ohse Y, Yoshida T. 8 cases whose diabetes mellitus could be normalized by a large quantity of weight loss. Foria Endocrinologica Japonica 2008;84:273 (in Japanese). Harayama T, Kusunoki C, Ohse Y, Yoshida T. 8 cases whose diabetes mellitus could be normalized by a large quantity of weight loss. Foria Endocrinologica Japonica 2008;84:273 (in Japanese).
6.
go back to reference Kusunoki C, Harayama T, Umekawa T, Yoshida T. Three obese cases of type 2 diabetes mellitus associated with metabolic syndrome, who could substantially lower their insulin requirement by losing body weight. J Japan Diab Soc. 2007;50:247–54. (in Japanese, Abstract in English). Kusunoki C, Harayama T, Umekawa T, Yoshida T. Three obese cases of type 2 diabetes mellitus associated with metabolic syndrome, who could substantially lower their insulin requirement by losing body weight. J Japan Diab Soc. 2007;50:247–54. (in Japanese, Abstract in English).
7.
go back to reference Smith DE, Heckemeyer T, Cuzuk M, Kratt PP, Mason DA. Motivational interviewing to improve adherence to a behavioral weight-control program for older obese women with NIDDM: a pilot study. Diabetes Care. 1997; 20:52–4. Smith DE, Heckemeyer T, Cuzuk M, Kratt PP, Mason DA. Motivational interviewing to improve adherence to a behavioral weight-control program for older obese women with NIDDM: a pilot study. Diabetes Care. 1997; 20:52–4.
8.
go back to reference Yoshida T. The knack of obesity treatment for Japanese obese patients. Tokyo: Makino Publishing Co; 2008. (in Japanese). Yoshida T. The knack of obesity treatment for Japanese obese patients. Tokyo: Makino Publishing Co; 2008. (in Japanese).
9.
go back to reference Diabetes Prevention Program Research Groups. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformine. N Engl J Med. 2002; 346:393–403. Diabetes Prevention Program Research Groups. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformine. N Engl J Med. 2002; 346:393–403.
10.
go back to reference Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67:152–62.PubMedCrossRef Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67:152–62.PubMedCrossRef
11.
go back to reference Sjöstrom L, Rissanen A, Andersen T, Bildrin M, Golay A, Koppeschaar HPF, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167–73.PubMedCrossRef Sjöstrom L, Rissanen A, Andersen T, Bildrin M, Golay A, Koppeschaar HPF, Krempf M. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet. 1998;352:167–73.PubMedCrossRef
12.
go back to reference Torgerson JS, Hauptman J, Boldrin MN, Sjöstrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155–61.PubMedCrossRef Torgerson JS, Hauptman J, Boldrin MN, Sjöstrom L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004;27:155–61.PubMedCrossRef
13.
go back to reference Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, The STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072–7.PubMedCrossRef Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, The STOP-NIDDM Trial Research Group. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet. 2002;359:2072–7.PubMedCrossRef
14.
go back to reference Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397–415.PubMed Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord. 1992;16:397–415.PubMed
15.
go back to reference Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001;24:1957–60.PubMedCrossRef Gokcel A, Karakose H, Ertorer EM, Tanaci N, Tutuncu NB, Guvener N. Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001;24:1957–60.PubMedCrossRef
16.
go back to reference Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord. 2002;26:S34–7.PubMedCrossRef Krejs GJ. Metabolic benefits associated with sibutramine therapy. Int J Obes Relat Metab Disord. 2002;26:S34–7.PubMedCrossRef
17.
go back to reference Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JB, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JB, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.PubMedCrossRef
18.
go back to reference Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.PubMedCrossRef Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science. 1993;259:87–91.PubMedCrossRef
19.
go back to reference Steppan CM, Balley ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.PubMedCrossRef Steppan CM, Balley ST, Bhat S, Brown EJ, Banerjee RR, Wright CM, Patel HR, Ahima RS, Lazar MA. The hormone resistin links obesity to diabetes. Nature. 2001;409:307–12.PubMedCrossRef
20.
go back to reference Defronzo RA. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667–687. Defronzo RA. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667–687.
21.
go back to reference Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diab Res Clin Prac. 2004;66:S37–43.CrossRef Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diab Res Clin Prac. 2004;66:S37–43.CrossRef
Metadata
Title
Correlation between weight loss and improvement of diabetes mellitus among obese type 2 diabetic patients
Authors
Takuya Harayama
Toshihide Yoshida
Keiji Yoshioka
Akinori Kogure
Ryosuke Sakai
Tetsuya Yasui
Yuriko Kondo
Michiaki Fukui
Goji Hasegawa
Naoto Nakamura
Publication date
01-06-2013
Publisher
Springer Japan
Published in
Diabetology International / Issue 2/2013
Print ISSN: 2190-1678
Electronic ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-013-0107-1

Other articles of this Issue 2/2013

Diabetology International 2/2013 Go to the issue